SCHEMBL7259504

SCHEMBL7259504

C[C@H](O[Si](C)(C)C(C)(C)C)[C@@H](CCOc1ccc(-c2ccccc2)cc1)NC(=O)c1c[nH]cn1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.36
MAPT P10636 2/20 0.35
NPC1 O15118 1/20 0.35
LMNA P02545 1/20 0.35
CASP3 P42574 1/20 0.35
SENP8 Q96LD8 1/20 0.35
SENP7 Q9BQF6 1/20 0.35
SENP6 Q9GZR1 1/20 0.35
MME P08473 1/20 0.35
MMP3 P08254 1/20 0.34
SUCNR1 Q9BXA5 5/20 0.34
HDAC3 O15379 4/20 0.34
HDAC4 P56524 4/20 0.34
HDAC1 Q13547 4/20 0.34
HDAC7 Q8WUI4 4/20 0.34
HDAC2 Q92769 4/20 0.34
HDAC10 Q969S8 4/20 0.34
HDAC11 Q96DB2 4/20 0.34
HDAC8 Q9BY41 4/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7264002 0.86 NPC1 (0.37) MAPTNPC1LMNAPPARGPPARA
SCHEMBL7264021 0.84 FFAR1 (0.35) SMN1; SMN2MAPTNPC1LMNACASP3
SCHEMBL7451266 0.84 HPGD (0.37) SMN1; SMN2LMNA
SCHEMBL7259390 0.84 RAB9A (0.38) SMN1; SMN2NPC1LMNAPPARG
SCHEMBL7264336 0.84 FAAH (0.34) SMN1; SMN2MAPTNPC1HDAC6
SCHEMBL7259876 0.83 RAB9A (0.32) SMN1; SMN2NPC1LMNA
SCHEMBL7263916 0.83 REN (0.31) SMN1; SMN2
SCHEMBL7259380 0.83 SMN1; SMN2 (0.39) SMN1; SMN2MAPTNPC1LMNA
SCHEMBL7258701 0.82 MAPT (0.34) SMN1; SMN2MAPTNPC1
SCHEMBL7259495 0.81 LTB4R (0.36) SUCNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2003006437-A1 IMIDAZOLE DERIVATIVES AS ADENOSINE DEAMINASE INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-01-23 WO disclosed